SCHEMBL13828612

SCHEMBL13828612

CC1(C)NC(=O)N(c2ccc(Oc3ccccc3)nc2)C1=O

nearest known ligand 0.52

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
AR P10275 8/20 0.52
LMNA P02545 2/20 0.44
TSHR P16473 1/20 0.44
MAPK1 P28482 1/20 0.44
HTT P42858 1/20 0.44
MMP13 P45452 2/20 0.43
ALDH1A1 P00352 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
GPR84 Q9NQS5 1/20 0.39
OXTR P30559 1/20 0.39
AVPR1A P37288 1/20 0.39
BTK Q06187 1/20 0.39
GAA P10253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12593838 0.86 AR (0.46) ARLMNATSHRMAPK1HTT
SCHEMBL30939597 0.83 AR (0.46) ARLMNATSHRMAPK1HTT
SCHEMBL13721657 0.83 AR (0.46) ARLMNATSHRMAPK1HTT
SCHEMBL1980132 0.82 AR (0.50) ARLMNATSHRMAPK1HTT
SCHEMBL30939608 0.82 AR (0.50) ARLMNATSHRMAPK1HTT
SCHEMBL1772478 0.82 AR (0.55) ARLMNATSHRSMN1; SMN2
SCHEMBL1191959 0.82 AR (0.55) ARLMNATSHRMAPK1HTT
SCHEMBL30939562 0.82 AR (0.47) ARTSHRHTTMMP13ALDH1A1
SCHEMBL1979597 0.82 AR (0.47) ARTSHRHTTMMP13ALDH1A1
SCHEMBL1982711 0.81 AR (0.46) ARLMNATSHRHTTMMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200163964-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2020-05-28 US disclosed
US-10632118-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2020-04-28 US disclosed
US-20180021336-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2018-01-25 US disclosed
US-20180021336-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2018-01-25 US disclosed
US-9849131-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2017-12-26 US disclosed
US-9849131-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2017-12-26 US disclosed
US-20170065585-A1 IMIDAZOLIDINEDIONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2017-03-09 US disclosed
US-20170065585-A1 IMIDAZOLIDINEDIONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2017-03-09 US disclosed
US-20160058737-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2016-03-03 US disclosed
US-9216967-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2015-12-22 US disclosed
US-8722695-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2014-05-13 US disclosed
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2012-11-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180021336-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 AR 4780/4885LMNA 2187/4885TSHR 1840/4885
US-10632118-B2 Imidazolidinedione derivatives KCND3, KCNK3, KCNA3 AR 4780/4885LMNA 2187/4885TSHR 1840/4885
US-20170065585-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 AR 4780/4885LMNA 2187/4885TSHR 1840/4885
US-20160058737-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 AR 4780/4885LMNA 2187/4885TSHR 1840/4885
US-20200163964-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 AR 4780/4885LMNA 2187/4885TSHR 1840/4885
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 AR 4638/4885LMNA 2517/4885TSHR 1392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.